WDA: wholesale distribution authorisation

A wholesale distribution authorisation (WDA) is the licence needed to procure, hold, supply or export medicines in the EU other than to the public.

Also known as: wholesale dealer's licence, wholesale distribution licence, WDA(H)

3 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Legal basis
Articles 76 to 85 of Directive 2001/83/EC
Granted by
The Member State where the premises are, within 90 days of the application
Requires
Suitable premises, a designated responsible person and GDP compliance
Public record
EudraGMDP

How it works

Article 1(17) of Directive 2001/83/EC defines wholesale distribution as all activities consisting of procuring, holding, supplying or exporting medicinal products, apart from supplying them to the public. Article 77 makes those activities subject to an authorisation granted by the Member State where the premises are located, and the authorisation states the premises it covers. A holder of a manufacturing and importation authorisation may distribute the products that authorisation covers without a separate WDA, but a WDA never covers manufacture or import from third countries. Pharmacies that also wholesale need the authorisation for that activity.

Article 79 sets the minimum conditions: suitable and adequate premises, installations and equipment; staff, and in particular a qualified person designated as responsible, known in practice as the responsible person; and an undertaking to meet the obligations in Article 80. Those obligations include giving inspectors access at any time, obtaining medicines only from authorised wholesalers or manufacturers and supplying them only to persons authorised to receive them, verifying that medicines received are not falsified by checking the safety features, keeping an emergency plan for recalls, keeping records of every transaction for five years, maintaining a quality system and following good distribution practice.

The authorisation matters to a marketing authorisation holder in three ways. First, a holder that buys, stores or sells finished product it does not itself manufacture is wholesaling, and needs a WDA for the premises concerned or a contracted wholesaler that has one; Member States differ on how they treat companies that trade without physically holding stock. Second, Article 76 requires a distributor that brings a product in from another Member State, and is not the holder, to notify the holder and the competent authority, which is the legal hook for parallel import and parallel distribution notices. Third, wholesalers share the public service obligation in Article 81 to keep the market supplied. Authorisations, and the GDP certificates issued after inspection, are entered in EudraGMDP, where the status of a customer or supplier can be checked. Brokers, who negotiate sales without handling the product, do not need a WDA but must register under Article 85b.

What goes wrong

A marketing authorisation holder invoices and ships product from a warehouse that is not on any authorisation; the responsible person named on the authorisation has left, or is responsible in name only; supplier and customer qualification is done once and never repeated, so a customer whose authorisation was suspended is still supplied; a site holds a WDA but stores products, such as controlled drugs or cold-chain medicines, outside the scope listed on it; exports to third countries are assumed to be outside the rules, when Article 85a disapplies only some of the obligations; and group companies assume one affiliate's authorisation covers another legal entity at the same address. Each of these is a routine finding at a GDP inspection, and a critical finding can lead to suspension of the authorisation and a statement of non-compliance in EudraGMDP.

Timing

Under Article 78 of Directive 2001/83/EC the authority must complete its examination of a WDA application within 90 days of receiving it, normally after an inspection of the premises. After an inspection that shows compliance, a GDP certificate is issued within 90 days under Article 111(5). Records of purchases and sales must be kept for five years.

WDA: common questions

Who needs a wholesale distribution authorisation?

Any company that procures, holds, supplies or exports medicinal products in the EU other than to the public: wholesalers, logistics providers that store medicines, and marketing authorisation holders that trade finished product they do not manufacture. Manufacturers may distribute the products covered by their own manufacturing authorisation without a separate WDA.

What is a responsible person in wholesale distribution?

Article 79 of Directive 2001/83/EC requires a wholesaler to have a qualified person designated as responsible, usually called the responsible person or RP. The GDP guidelines make the RP personally responsible for the quality system, for approving suppliers and customers, and for recalls, returns and training. It is a different role from the qualified person who certifies batches at a manufacturer.

What is the difference between a WDA and an MIA?

An MIA authorises manufacture, including packaging, batch certification and import from outside the EEA. A WDA authorises buying, storing, supplying and exporting finished medicines. An MIA includes the right to distribute the products it covers; a WDA never allows manufacturing or importation, so a wholesaler that relabels or repackages needs an MIA as well.

Sources

  1. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use
  2. EUR-Lex: Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (2013/C 343/01)
  3. European Medicines Agency: Good distribution practice

Put your WDA question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.